Novel Immuno-Oncology Candidate

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries is executing a successful 'Pivot to Growth' strategy, transitioning from a generics-centric model to an innovation-driven biopharmaceutical company. This shift has yielded three consecutive years of revenue growth, driven by its specialty portfolio in CNS disorders and a burgeoning biosimilars pipeline. The company's integrated model, spanning complex generics, API manufacturing, and novel drug development, provides a durable competitive moat and positions it to address both affordability and unmet medical needs globally.

Therapeutic Areas